BR112022018536A2 - Método para o tratamento de infecções virais com monossacarídeos tipo hexose e seus análogos - Google Patents

Método para o tratamento de infecções virais com monossacarídeos tipo hexose e seus análogos

Info

Publication number
BR112022018536A2
BR112022018536A2 BR112022018536A BR112022018536A BR112022018536A2 BR 112022018536 A2 BR112022018536 A2 BR 112022018536A2 BR 112022018536 A BR112022018536 A BR 112022018536A BR 112022018536 A BR112022018536 A BR 112022018536A BR 112022018536 A2 BR112022018536 A2 BR 112022018536A2
Authority
BR
Brazil
Prior art keywords
analogues
treatment
viral infections
hexose
monosaccharides
Prior art date
Application number
BR112022018536A
Other languages
English (en)
Portuguese (pt)
Inventor
Priebe Waldemar
Fokt Izabela
Zielinski Rafal
Skora Stanislaw
Picker Donald
Klemp Walter
Original Assignee
Univ Texas
Moleculin Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Moleculin Biotech Inc filed Critical Univ Texas
Publication of BR112022018536A2 publication Critical patent/BR112022018536A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112022018536A 2020-03-16 2021-03-16 Método para o tratamento de infecções virais com monossacarídeos tipo hexose e seus análogos BR112022018536A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990337P 2020-03-16 2020-03-16
PCT/US2021/022622 WO2021188586A1 (en) 2020-03-16 2021-03-16 Method of treating viral infections with hexose type monosaccharides and analogs thereof

Publications (1)

Publication Number Publication Date
BR112022018536A2 true BR112022018536A2 (pt) 2022-11-29

Family

ID=75439533

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018536A BR112022018536A2 (pt) 2020-03-16 2021-03-16 Método para o tratamento de infecções virais com monossacarídeos tipo hexose e seus análogos

Country Status (11)

Country Link
US (1) US20230130134A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121060A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023518249A (cg-RX-API-DMAC10.html)
KR (1) KR20220166800A (cg-RX-API-DMAC10.html)
CN (1) CN115515601B (cg-RX-API-DMAC10.html)
AU (1) AU2021239927A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018536A2 (cg-RX-API-DMAC10.html)
CA (1) CA3170872A1 (cg-RX-API-DMAC10.html)
IL (1) IL296389A (cg-RX-API-DMAC10.html)
MX (1) MX2022011488A (cg-RX-API-DMAC10.html)
WO (1) WO2021188586A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
ATE544865T1 (de) * 2002-07-12 2012-02-15 Us Gov Health & Human Serv Assays für den zusammenbau von ebola-virus- nukleocapsiden
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
EP1986660A4 (en) * 2006-02-24 2009-08-26 Univ Texas HEXOSE COMPOUNDS FOR CANCER TREATMENT
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
US8927506B2 (en) 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity
US8173636B2 (en) * 2009-04-03 2012-05-08 Achillion Pharmaceuticals, Inc. Hydroxylthienoquinolones and related compounds as anti-infective agents
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
EP3517117A1 (en) * 2018-01-30 2019-07-31 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Also Published As

Publication number Publication date
JP2023518249A (ja) 2023-04-28
CN115515601A (zh) 2022-12-23
CN115515601B (zh) 2026-06-16
IL296389A (en) 2022-11-01
AU2021239927A1 (en) 2022-10-06
MX2022011488A (es) 2023-03-01
EP4121060A1 (en) 2023-01-25
KR20220166800A (ko) 2022-12-19
US20230130134A1 (en) 2023-04-27
WO2021188586A1 (en) 2021-09-23
CA3170872A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
MX2022011488A (es) Método para tratar infecciones virales con monosacáridos tipo hexosa y análogos de los mismos.
BR112022005896A2 (pt) Inibidores da mek para o tratamento de infecções causadas por hantavírus
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
CO2019013047A2 (es) Composiciones sólidas para administración oral
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
BR112014009528A8 (pt) métodos e composições para tratar eritropoiese ineficaz
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112023001143A2 (pt) Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo
BR112014008425A2 (pt) composição para o uso na promoção de angiogênese intestinal e de absorção de nutriente e de tolerância a alimentação enteral e/ou na prevenção e/ou no tratamento de inflamação intestinal e/ou na recuperação após a lesão e a cirurgia intestinal
CO2024016912A2 (es) Compuestos de indolinilo antivirales y usos de estos
BR112023001129A2 (pt) Pró-fármacos antivirais, formulações farmacêuticas e métodos
MX2020002191A (es) Agentes antivirales contra la hepatitis b.
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
BR112021022752A2 (pt) Composições e métodos para potencializar o efeito músculo-esquelético de um ou mais aminoácidos anabólicos
BR112019008411A2 (pt) materiais e métodos para o controle de biofilme
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
BR112015031088A2 (pt) composições e métodos de imunização contra c. difficile
BR112015019220A2 (pt) uso de um inibidor de helicase-primase; uso de uma composição farmacêutica; e composição farmacêutica
BR112014027646A2 (pt) método para tratar um indivíduo quanto a um distúrbio proliferativo celular, e método para prevenir ou inibir a perda induzida por uv da atividade de udp-glucuronosiltransferase (ugt) em um indivíduo
UY39172A (es) Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e
BR112022019685A2 (pt) Composições de ácido siálico para uso na inibição ou no tratamento de infecções por coronavírus
BR112022018504A2 (pt) Usos de uma composição
BR112022009803A2 (pt) Variantes de sacarose invertase